

Stroke Recovery – Pharmacological Treatment Concepts in the acute and sub-acute phase

Thursday, 18 May 2017, 12:15-13:45 (Meeting Hall I)

Chairmen: Michael Chopp, USA
Michael Brainin, Austria

Special Acknowledgement:
ESO-EAST - Achievements 2016 and future initiatives
Robert Mikulik, Czech Republic

- **New rigorous preclinical trials of Cerebrolysin for stroke**
Michael Chopp, USA
- **Cerebrolysin's evidence in acute stroke - a clinical review**
Milan Vosko, Austria
- **Challenges & Opportunities in Motor Recovery**
Dafin Muresanu, Romania
- **Stroke and Cognition**
Michael Brainin, Austria

EVER Rehabilitationset and Scales booklet for free!

Neurorehabilitation after Stroke - by Austrian rehabilitation experts
Please visit the EVER booth to register for this symposium. As registered participant you'll receive the EVER Rehabilitationset (DVD and booklet) with essential exercises and the EVER Scales booklet directly after the symposium. (limited - while stock lasts)





SMALL MOMENT. BIG DIFFERENCE.
Last month, Paul was suffering from cognitive and motor impairment. Today, he's making his next big move.

- Improvement of motor functions
- Regain full independence
- Early recovery after stroke
- Increase quality of life

Muresanu, et al., 2016

ABBREVIATED PRESCRIBING INFORMATION: Name of the medicinal product: Cerebrolysin® - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of porcine brain-derived peptide preparation (Cerebrolysin® concentrate) in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: Organic, metabolic and neurodegenerative disorders of the brain, especially senile dementia of Alzheimer's type - Post-apoplectic complications - Craniocerebral trauma; post-operative trauma, cerebral contusion or concussion. Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.



Cerebrolysin®
Reconnecting Neurons.
Empowering for Life.